Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer

BACKGROUND: Tyrosine kinase inhibitors (TKIs), such as gefitinib, are widely used as standard treatments for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, the subsequent inevitable drug resistance has become a major challenge in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Mengnan, Wang, Wei, Zhou, Jian, Chang, Meijia, Peng, Wenjun, Zhang, Ge, Li, Jing, Li, Huayin, Bai, Chunxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139041/
https://www.ncbi.nlm.nih.gov/pubmed/32274137
http://dx.doi.org/10.21037/jtd.2019.12.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139041/
https://www.ncbi.nlm.nih.gov/pubmed/32274137
http://dx.doi.org/10.21037/jtd.2019.12.106

Ejemplares similares